MILI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mili, and when can generic versions of Mili launch?
Mili is a drug marketed by Aurobindo Pharma Ltd and is included in one NDA.
The generic ingredient in MILI is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MILI?
- What are the global sales for MILI?
- What is Average Wholesale Price for MILI?
Summary for MILI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Drug Prices: | Drug price information for MILI |
| DailyMed Link: | MILI at DailyMed |
US Patents and Regulatory Information for MILI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | MILI | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 205449-001 | Jul 7, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
